Immunomodulation of advancedsol;progressive renal cell cancer

摘要

At present, there are two major lines of approach for the immunotherapy of renal cell carcinoma (RRC): adoptive transfer of effector cells of the immune system activatedin vitro and/oractivation of immune effectorsin vivoby infusion of cytokines. Objective responses (ORs) are in the range of 15ndash;30percnt; making these concepts experimental rather than established therapy.